Colgate-Palmolive (NYSE:CL) beat Q1 2026 Earnings and Revenue forecasts, posting adjusted EPS of USD 0.97 and net sales of USD 5.32 billion, but revised its gross Margin guidance downward after flagging USD 300 million in additional costs tied to the U.S.-Iran conflict.

Key Highlights

  • Adjusted EPS of USD 0.97 beat the USD 0.94 consensus estimate by 3.19%; reported Net Income came in at USD 646 million, or USD 0.80 per share.
  • Net sales rose 8.4% year-on-year to USD 5.32 billion, ahead of the USD 5.22 billion analyst forecast.
  • The company flagged USD 300 million in additional raw material and logistics costs for 2026, driven by the U.S.-Iran conflict.
  • Gross Margin guidance was revised to a year-on-year decline; annual EPS growth guidance in the low-to-mid single-digit range was maintained.
  • North America volumes fell 3.2%, while Asia Pacific and Latin America drove overall Volume growth of 1.1%.

A Beat With a Caveat

Colgate-Palmolive (NYSE:CL) posted net sales of USD 5.32 billion in Q1 2026, exceeding analyst expectations of USD 5.22 billion compiled by LSEG. Adjusted EPS of USD 0.97 cleared the USD 0.94 consensus, a 3.19% Earnings surprise. On a reported basis, Net Income was USD 646 million, or USD 0.80 per share, down from USD 690 million, or USD 0.85 per share, a year earlier. The stock rose approximately 3% in early trading on May 1.

The result, however, comes with a structural qualifier. Colgate joins rivals including Unilever (NYSE:UL) and Procter & Gamble (NYSE:PG) in warning of significant cost pressures stemming from the U.S.-Iran conflict, which has disrupted global Supply chains and pushed Commodity prices sharply higher. The company now expects approximately USD 300 million in additional raw material and logistics costs for the full year, assuming oil at roughly USD 110 per barrel. That figure breaks down to two-thirds raw materials and one-third logistics, with oil byproducts, resins, and Petrochemicals running more than 20% above prior-year levels and logistics costs up nearly 10%.

Margins Under Pressure, EPS Guidance Held

The most consequential disclosure of the quarter was the revision to gross Margin guidance. Having previously expected a year-on-year improvement, Colgate now anticipates a decline for the full year. Despite this, management reaffirmed annual EPS growth guidance in the low-to-mid single-digit range and Organic Sales growth of 1% to 6%, relying on Revenue growth management, selective premium pricing, and productivity savings to absorb the shortfall.

The Strategic Growth and Productivity Program was also updated, with annualised savings now targeted at USD 200 million to USD 300 million by programme completion on December 31, 2028. The majority of those benefits are weighted toward 2027 and 2028, providing limited near-term Margin relief. TD Cowen analysts noted that while management pointed to its full toolkit for managing costs, executives sounded cautious about raising prices at a time when consumers are visibly value-conscious.

Geographic Split: Emerging Markets Carry the Weight

Overall volumes grew 1.1%, entirely on the back of emerging market strength. Asia Pacific was the standout, with China and India both showing meaningful acceleration. The Colgate Brand in China delivered mid-single-digit Volume growth against a flat-to-declining category, while the Hawley & Hazel Business showed tangible progress through product innovation and improved omnichannel execution. Latin America continued its run of consistent delivery, with Mexico and Brazil as the primary drivers, supported by disciplined Revenue growth management and AI-driven promotional analytics.

North America, by contrast, declined 3.2% in Volume and 1.8% in net sales. U.S. consumer sentiment, as measured by the University of Michigan, fell to a record low in its 70-plus-year survey history as of April 10. Delayed shelf resets, late product shipments, and rising competitive promotional intensity in oral care all contributed to the weakness. Management guided for sequential improvement through the balance of 2026, pointing to Brand interventions, accelerated innovation, and revised retail promotional strategies, but acknowledged the recovery will take time.

Hill's Pet Nutrition was a quiet outperformer. Excluding the planned private-label pet food exit, Organic Sales grew 4.8%, with U.S. sales up 5% against a roughly flat category. Prescription Diet posted double-digit growth in key therapeutic segments, underpinned by its veterinarian endorsement model and premium science-backed positioning. The private-label drag is expected to largely disappear by the second half of 2026.

Conclusion: Execution Intact, Margin Risk Elevated

Colgate's Q1 result confirms that its emerging market positioning and Hill's premium platform remain reliable sources of growth. The EPS beat, 8.4% sales growth, and broad-based international Volume acceleration reflect disciplined execution in a difficult environment.

The challenge ahead is one of cost absorption. A USD 300 million headwind, a downward gross Margin revision, and a U.S. consumer under meaningful financial stress collectively tighten the Margin of error for the remainder of the year. The Strategic Growth and Productivity Program's expanded savings target provides a credible medium-term buffer, but its benefits arrive largely in 2027 and 2028. Near-term, the company must navigate elevated input costs, a fragile North American consumer, and a competitive promotional landscape, all while sustaining the Brand Investment that underpins its international growth momentum. How well it manages that balance through Q2 and Q3 will be the real test of management's guidance confidence.